Literature DB >> 19751494

alpha-Luminol prevents decreases in glutamate, glutathione, and glutamine synthetase in the retinas of glaucomatous DBA/2J mice.

Juliet R Gionfriddo1, Kate S Freeman, Allyson Groth, Virginia L Scofield, Khaleel Alyahya, James E Madl.   

Abstract

OBJECTIVE: To test the hypothesis that in DBA/2J mice, oxidative stress decreases glutamine synthetase (GS) levels resulting in a loss of neuronal glutamate and that the antioxidant alpha-luminol (GVT) decreases this stress and glutamate loss in some types of glaucoma. ANIMALS: DBA/2J mice were separated into two groups, of which one was not treated, and the other treated with GVT in the drinking water. At 7 months of age, retinas were examined from five untreated DBA/2J mice, seven GVT-treated mice, and five C57BL/6 mice (negative controls).
METHODS: Serial 0.5 microm plastic sections were immunogold stained for glutamate, GS, and total glutathione, followed by image analysis for staining patterns and density.
RESULTS: Focal decreases in glutamate immunostaining were common in the inner nuclear layer (INL) of DBA/2J retinas, but not in C57BL/6 or GVT-treated DBA/2J retinas. Decreases in glutathione and GS immunostaining were found in DBA/2J retinal regions where neuronal glutamate immunostaining was reduced. Retinas from GVT-treated DBA/2J had no significant decreases in INL levels of glutamate, glutathione, or GS.
CONCLUSIONS: Retinas of dogs with primary glaucoma are reported to have focal depletion of neuronal glutamate. In DBA/2J mice, similar changes occur prior to the development of clinical disease. In these focal glutamate-depleted regions, levels of glutathione and GS are also reduced, consistent with the hypothesis that oxidative stress contributes to retinal changes in glaucoma. The ability of GVT, an antioxidant, to inhibit retinal abnormalities in DBA/2J mice provides further support for this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19751494     DOI: 10.1111/j.1463-5224.2009.00722.x

Source DB:  PubMed          Journal:  Vet Ophthalmol        ISSN: 1463-5216            Impact factor:   1.644


  8 in total

1.  Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of glaucoma.

Authors:  Dongwook Lee; Myoung Sup Shim; Keun-Young Kim; You Hyun Noh; Heemin Kim; Sang Yeop Kim; Robert N Weinreb; Won-Kyu Ju
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-18       Impact factor: 4.799

Review 2.  Oxidative stress and potential applications of free radical scavengers in glaucoma.

Authors:  Mutay Aslan; Serdar Dogan; Ertan Kucuksayan
Journal:  Redox Rep       Date:  2013-03-06       Impact factor: 4.412

Review 3.  Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis.

Authors:  Raffaele Nuzzi; Federico Tridico
Journal:  Front Neurosci       Date:  2017-09-05       Impact factor: 4.677

Review 4.  The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration.

Authors:  Marita Pietrucha-Dutczak; Marialaura Amadio; Stefano Govoni; Joanna Lewin-Kowalik; Adrian Smedowski
Journal:  Front Neurosci       Date:  2018-11-15       Impact factor: 4.677

5.  Oxidative stress in the retina and retinal pigment epithelium (RPE): Role of aging, and DJ-1.

Authors:  Mala Upadhyay; Caroline Milliner; Brent A Bell; Vera L Bonilha
Journal:  Redox Biol       Date:  2020-07-17       Impact factor: 11.799

6.  α-Lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction.

Authors:  Denise M Inman; Wendi S Lambert; David J Calkins; Philip J Horner
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

7.  GABA and Glutamate Uptake and Metabolism in Retinal Glial (Müller) Cells.

Authors:  Andreas Bringmann; Antje Grosche; Thomas Pannicke; Andreas Reichenbach
Journal:  Front Endocrinol (Lausanne)       Date:  2013-04-17       Impact factor: 5.555

8.  Antioxidant Treatment Limits Neuroinflammation in Experimental Glaucoma.

Authors:  Xiangjun Yang; Gözde Hondur; Gülgün Tezel
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-04-01       Impact factor: 4.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.